China Formulators Supplier & Suppliers: Precision Botanical R&D and Scaled Formulation

A standard extract broker or toll-extractor functions as a volume processor with narrow quality metrics (often relying solely on loss on drying, ash content, and crude spectrophotometric UV assays). In contrast, MedGence functions as an integrated technology CRO/CDMO. We perform molecular active screening, test origin-season potency variance, develop and validate proprietary HPLC/HPTLC chromatographic fingerprints, run GLP animal toxicology, carry out Phase I–IV clinical investigations, and formulate finished dosage forms (capsules, tablets, softgels, liquids) with complete ICH stability and regulatory filing dossiers.

Our operational framework is strictly built around "Entrusted Contract R&D and Manufacturing". Under formal bilateral non-disclosure and intellectual property assignment covenants, all screening results, extraction parameters, excipient matrices, and analytical methods developed for your project belong exclusively to your organization. Data access within our Changsha research center is firewalled, ensuring formulation parameters are never disclosed or commercialized with third parties.

We utilize high-performance thin-layer chromatography (HPTLC) for qualitative botanical identity confirmation, high-performance liquid chromatography (HPLC with DAD/ELSD/MS detectors) for exact active compound quantification, and gas chromatography (GC/GC-MS) for volatile oils, residual solvent clearance, and pesticide multi-residue screening. Additionally, our labs employ full chromatographic fingerprinting to verify batch-to-batch consistency against certified botanical reference standards.

Yes. Our analytical and preclinical toxicology outputs are formatted to comply with international submission standards. We furnish validated stability testing data (accelerated and real-time per ICH guidelines), in vitro and in vivo toxicology packages (including LD50, 90-day repeat dose, and Ames genotoxicity), and extraction method validation dossiers required for New Dietary Ingredient (NDI) notifications, Self-Affirmed GRAS dossiers, and European Novel Food applications.

We manufacture both concentrated bulk active intermediates (concentrated liquids, vacuum-dried extract powders, viscous pastes, supercritical volatile oils) and finished commercial consumer packaging. Supported finished formats include hard gelatin and vegetarian HPMC capsules, rotary-die softgels, coated and sublingual tablets, oral drink ampoules, soluble granular sachets, and effervescent formulations, supported by automated blister packing and bottling lines.

Secondary plant metabolites vary dramatically based on altitude, sunshine exposure, rainfall, and harvest timing. An extract manufactured from autumn-harvested bark can possess 3x to 5x higher active fraction density than spring-harvested material. By systematically profiling and mapping the botanical harvest window and geographic origin, we eliminate active fluctuation at the source, allowing formulators to hit target therapeutic doses with lower excipient mass and superior cost efficiency.